From: Recent advances in pharmacological diversification of Src family kinase inhibitors
Type of kinase inhibitor | Approved drugs | Target site |
---|---|---|
Type I kinase inhibitors | Bosutinib, Crizotinib, Dasatinib, Erlotinib, Gefitinib, Lapatinib, Pazopanib, Ruxolitinib, Sunitinib, Vandetanib, and Vemurafenib | Active ATP binding sites |
Type II kinase inhibitors | Imatinib, Ponatinib | Inactive conformation of Substrate |
Type III or allosteric inhibitors | RO0281675 | Allosteric sites |
Type IV or substrate-directed inhibitors | ON012380 | ATP noncompetitive inhibitors |
Type V or covalent inhibitors | Ibrutinib, Afatinib, and Neratinib | Cysteine side chains of kinases |